abstract |
The present invention relates to a combination comprising a Src kinase inhibitor and the cytotoxic substance gemcitabine, a pharmaceutical composition comprising such a combination, and its use in the treatment or prevention of cancer, in particular in the treatment or prevention of pancreatic cancer. |